James Bochnowski
Founder & Managing Member @ Delphi Ventures
Menlo Park, United States
James Bochnowski is a Series C investor at Delphi Ventures in Menlo Park focused on Medical Device and Health Care. Jim founded Delphi Ventures in 1988. His focus is on medical devices and biotechnology.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries James Bochnowski invests in
Stages James Bochnowski invests in
Countries James Bochnowski invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical Device 4 (33%)
- Health Care 3 (25%)
- Manufacturing 2 (17%)
- Eyewear 1 (8%)
- Medical 1 (8%)
Stage
- Series C 3 (25%)
- Series D 3 (25%)
- Series A 2 (17%)
- Series B 2 (17%)
- Seed 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Heartbeat is a platform for millennial women to join, provide feedback to, and promote brands via their personal networks. Heartbeat has matched the millennial generation’s natural passion for self-promotion with a turn-key solution for brands to engage Ambassadors at scale.Coordinating large-scale Ambassador campaigns used to take 6 months. | $450K / Seed / Jul 17, 2017 | ||
| Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new optionfor the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany. | $20M / Series D / Apr 08, 2014 | ||
| Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new optionfor the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany. | $26M / Series C / Mar 06, 2012 | ||
| PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses. | $45M / Series D / Apr 07, 2011 | ||
| ELENZA, Inc. is developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. Theseelectro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life. | $24M / Series B / Feb 08, 2011 | ||
| PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information.Specialtieslaser, medical device, eschemic, stroke,infrared | $50M / Series D / May 22, 2009 | ||
| ELENZA, Inc. is developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. Theseelectro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life. | $6M / Series B / Dec 18, 2008 | ||
| PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses. | $30M / Series C / Oct 23, 2008 | ||
| ELENZA, Inc. is developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. Theseelectro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life. | $497K / Series A / Jul 01, 2008 | ||
| PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses. | $23.8M / Series B / Jan 09, 2008 | ||
| See all 12 investments → | |||
Co-Investors
About Delphi Ventures
Delphi Ventures is a venture capital firm that has focused on investing in biotechnology and medical devices for over two decades. With more than $1.1 billion in committed capital, Delphi Ventures has funded over 170 companies. More than 110 of our portfolio companies have either completed an initial public offering or have been acquired by a leading healthcare corporation.
Delphi Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
James Bochnowski
Founder & Managing Member
|
|||
Matthew T. Potter
CFO| Partner
|
|||
David L. Douglass
General Partner
|
|||
Deepika R Pakianathan
General Partner
|
|||
Doug Roeder
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does James Bochnowski invest in?
James Bochnowski invests primarily in Medical Device, Health Care and Manufacturing startups, most often at Series C and Series D stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact James Bochnowski?
Public channels for James Bochnowski include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did James Bochnowski last invest?
The most recent investment recorded for James Bochnowski closed in Jul 2017. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
